Skip to main content
SpringerLink
Log in

Growth inhibition of DMBA-induced rat mammary carcinomas by the antiandrogen flutamide

  • Original Paper
  • Published:
Journal of Cancer Research and Clinical Oncology Aims and scope Submit manuscript

Abstract

Antiandrogens have sporadically been reported to exert antitumor activities in both pre-and post-menopausal breast cancer. To explore the possibility of using the pure antiandrogen flutamide (FLU) in breast cancer therapy, rats bearing DMBA-induced mammary tumors were treated with FLU, dihydrotestosterone (DHT), or FLU plus DHT. FLU was administered orally, at doses comparable to those used in the treatment of prostate cancer patients. FLU-treated animals had a significantly smaller average tumor area than controls from day 11 up to the end of the experiment (day 20). A similar reduction of tumor growth was observed in rats given DHT and in those treated with DHT plus FLU. Plasma levels of LH, FSH, P, 17-OH P, E2 and DHEA measured at the end of experiment did not differ between treated animals and controls. Results demonstrate that the antiandrogen FLU and the full androgen DHT exert similar inhibitory effects on the growth of dimethylbenz(a)anthracene (DMBA)-induced rat mammary tumors. Moreover, data show that plasma steroids levels are unaffected by FLU treatment. This finding rules out any antitumor effect dependent on the reduction of adrenal and gonadal steroidosynthesis, and makes it appear more likely that androgen receptors are involved in the antiproliferative effect of FLU.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

AR:

Androgen receptors

DHEA :

Dehydroepiandrosterone

DHT :

Dihydrotestosterone

DMBA :

7,12-Dimethylbenz(a)anthracene

E 2 :

17β-Estradiol

FLU :

Flutamide

P :

Progesterone

17-OH P :

17-Hydroxy-progesterone

References

  • Asselin J, Labrie F (1977) Effects of estradiol and prolactin on steroid receptor levels in 7,12-dimethylbenz(a)anthracene-induced mammary tumors and uturus in the rat. J Steroid Biochem 9:1079–1082

    Google Scholar 

  • Asselin J, Mélacon R, Moachon G, Bélanger A (1980) Characteristics of binding to estrogen, androgen, progestin and glucocorticoid receptors in 7,12-dimethylbenz(a)anthracene-induced mammary tumors and their hormonal control. Cancer Res 40:1612–1622

    Google Scholar 

  • Ayub M, Levell M (1987) Inhibition of rat testicular 17-hydroxylase and 17,20-lyase activities by anti-androgens (flutamide, hydroxyflutamide, RU23908, cyproterone acetate) in vitro. J Steroid Biochem 28:43–47

    Google Scholar 

  • Ayub M, Levell M (1990) Suppression of plasma androgens by the antiandrogen flutamide in prostatic cancer patients treated with Zoladex, a GnRH analogue. Clin Endocrinol 32:329–339

    Google Scholar 

  • Balzano S, Cappa M, Migliari R, Scarpa R, Danielli E, Campus G, Pintus C, Sica V, Martino E (1988) The effect of flutamide on basal and ACTH-stimulated plasma levels of adrenal androgens in patients with advanced prostate cancer. J Endocrinol Invest 11:693–696

    Google Scholar 

  • Benz C, Hollander C, Miller B (1986) Endocrine-responsive pancreatic carcinoma: steroid binding and cytotoxicity studies in human tumor cell lines. Cancer Res 46:2276–2281

    Google Scholar 

  • Boccuzzi G, Brignardello E, Massobrio M, Bonino L (1987) Breast duct fluid dehydroepiandrosterone sulphate in fibrocystic disease. Eur J Cancer Clin Oncol 23:1099–1102

    Google Scholar 

  • Brann D, Putnam C, Mahesh V (1990) Similarities and differences in progesterone and androgens in modulation of LH, FSH, and PRL release: unexpected properies of flutamide. J Steroid Biochem 36:287–294

    Google Scholar 

  • Bretani M, Franco E, Oshima C, Pacheco M (1986) Androgen, estrogen and progesterone receptor levels in malignant and benign breast tumours: a multivariate analysis approach. Int J Cancer 38:637–640

    Google Scholar 

  • Brogden R, Clissold S (1989) Flutamide: a preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in advanced prostatic cancer. Drugs 38:185–203

    Google Scholar 

  • Brogden R, Chrisp P (1991) Flutamide: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in advanced prostatic cancer. Drugs Aging 1:104–115

    Google Scholar 

  • Bryan R, Mercer R, Bennet M, Rennie G, Lie T, Morgan F (1984) Androgen receptors in breast cancer. Cancer 54:2436–2439

    Google Scholar 

  • Couzinet B, Pholsena M, Young J, Schaison G (1993) The impact of a pure anti-androgen (flutamide) on LH, FSH, androgens and clinical status in idiopathic hirsutism. Clin Endocrinol 39:157–162

    Google Scholar 

  • Daneshgari F, Crawford D (1993) Endocrine therapy of advanced carcinoma of the prostate. Cancer 71:1089–1097

    Google Scholar 

  • Dauvois S, Li S, Martel C, Labrie F (1989) Inhibitory effect of androgens on DMBA-induced mammary carcinoma in the rat. Breast Cancer Res Treat 14:299–306

    Google Scholar 

  • Di Monaco M, Brignardello E, Leonardi L, Gatto V, Gallo M, Pizzini A, Boccuzzi G (1993) The antiandrogen flutamide inhibits growth of MCF-7 human breast cancer cell line. Int J Oncol 2:653–656

    Google Scholar 

  • Doberauer C, Niederle N, Schmidt C (1988) Advanced male breast cancer treatment with the LHRH analogue buserelin alone or in combination with the antiandrogen flutamide. Cancer 62:474–478

    Google Scholar 

  • Etreby M El, Habenicht U, Louton T, Nishino Y, Schroder H (1987) Effect of cyproterone acetate in comparison to flutamide and megestrol acetate on the ventral prostate, seminal vescicle and adrenal glands of adult male rats. Prostate 11:361–375

    Google Scholar 

  • Garcia M, Rochefort H (1978) Androgen effects mediated by estrogen receptor in 7,12-diemethylbenz(a)anthtacene-induced rat mammary tumors. Cancer Res 38:3922–3929

    Google Scholar 

  • Gordon G, Halden A, Horn Y, Fuery J, Parsons R, Walter R (1973) Calusterone (7,17-dimethyltestosterone) as primary and secondary therapy of advanced breast cancer. Oncology 28:138–146

    Google Scholar 

  • Jordan V (1976) Effect of tamoxifen (ICI 46,474) on initiation and growth of DMBA-induced rat mammary carcinomas. Eur J Cancer 12:419–424

    Google Scholar 

  • Kennedy B (1958) Fluoxymesterone therapy in treatment of advanced breast cancer. N Engl J Med 259:673–675

    Google Scholar 

  • Labrie F, Dupont A, Belanger A, Lacourciere Y, Beland L, Cusan L, Lachance R (1990) Complete response to combination therapy with an LHRH agonist and flutamide in metastatic male breast cancer: a case report. Clin Invest Med 13:275–278

    Google Scholar 

  • MacIndoe J, Etre L (1981) An antiestrogenic action of androgens in human breast cancer cells. J Clin Endocrinol Metab 53:836–842

    Google Scholar 

  • Marugo M, Bernasconi D, Miglietta L, Fazzuoli L, Ravera F, Casullo S, Giordano G (1992) Effects of dihydrotestosterone and hydroxyflutamide on androgen receptors in cultured human breast cancer cells (EVSA-T). J Steroid Biochem Mol Biol 42:547–554

    Google Scholar 

  • Maucher A, Angerer E von (1993) Antiproliferative activity of Casodex (ICI 176.334) in hormone dependent tumours. J Cancer Res Clin Oncol 119:669–674

    Google Scholar 

  • Miller W, Telford J, Dixon J, Hawkins R (1985) Androgen receptor activity in human breast cancer and its relationship with oestrogen and progesterone receptor activity. Eur J Cancer Clin Oncol 21:539–541

    Google Scholar 

  • Milward M, Cantwell B, Dowsett M, Carmichael J, Harris A (1991) Phase II clinical and endocrine study of anandron (RU-23908) in advanced post-menopausal breast cancer. Br J Cancer 63:763–764

    Google Scholar 

  • Neri R (1989) Pharmacology and pharmacokinetics of flutamide. Suppl Urol 34:19–21

    Google Scholar 

  • Neri R, Peets E (1975) Biological aspects of antiandrogens. J Steroid Biochem 6:815–822

    Google Scholar 

  • Neri R, Florance K, Koziol P, Van Cleave S (1972) A biological profile of a nonsteroidal antiandrogen, SCH 13521 (4′-nitro-3′-trifluromethylisobutyranilide). Endocrinology 91:427–437

    Google Scholar 

  • Perrault D, Logan D, Stewart D, Bramwell V, Paterson A, Eisenhauer E (1988) Phase II study of flutamide in patients with metastatic breast cancer. A National Cancer Institute of Canada Clinical Trials Group study. Invest New Drugs 6:207–210

    Google Scholar 

  • Poulin R, Baker D, Labrie F (1988) Androgens inhibit basal and estrogen induced cell proliferation in the ZR-75-1 human breast cancer cell line. Breast Cancer Res Treat 12:213–225

    Google Scholar 

  • Poulin R, Simard J, Labrie C, Peticlerc L, Dumont M, Lagace L, Labrie F (1989) Down-regulation of estrogen receptors by androgens in the ZR-75-1 human breast cancer cell line. Endocrinology 125:392–399

    Google Scholar 

  • Poyet P, Labrie F (1985) Comparison of the antiandrogenic androgenic activities of flutamide, cyproterone acetate, and megestrol acetate. Mol Cell Endocrinol 32:283–288

    Google Scholar 

  • Radwanski E, Perentesis G, Symchowicz S, Zarpaglione N (1989) Single and multiple dose pharmacokinetic evaluation of flutamide in normal geriatric volunteers. J Clin Pharmacol 29:554–558

    Google Scholar 

  • Robinson S, Jordan V (1987) Reversal of the antitumor effects of Tamoxifen by progesterone in the 7,12-dimethylbenz(a)anthraceneinduced rat mammary carcinoma model. Cancer Res 47:5386–5390

    Google Scholar 

  • Secreto G, Recchione C, Zambetti M, Fariselli G, Ballerini P (1988) Hormonal changes induced by the pure antiandrogen flutamide in postmenopausal women with advanced breast cancer. Eur J Cancer Clin Oncol 24:867–872

    Google Scholar 

  • Simard J, Luthy I, Guay J, Belanger A, Labrie F (1986) Characteristics of interaction of the antiandrogen flutamide with the androgen receptor in various target tissues. Mol Cell Endocrinol 44:261–270

    Google Scholar 

  • Soloway M, Matzkin H (1993) Antiandrogenic agents as monotherapy in advanced prostatic carcinoma. Cancer 71:1083–1088

    Google Scholar 

  • Spinola P, Marchetti B, Merand Y, Belanger A, Labrie F (1988) Effects of aromatase inhibitor 4-hydroxyandrostenedione and the antiandrogen flutamide on growth and steroid levels in DMBA-induced rat mammary tumours. Breast Cancer Res Treat 12:287–296

    Google Scholar 

  • Tormey D, Lippman M, Cassidy J (1983) Evaluation of tamoxifen doses with and without fluoxymesterone in advanced breast cancer. Ann Intern Med 98:139–143

    Google Scholar 

  • Tucker H, Crook J, Chesterson G (1988) Nonsteroidal antiandrogens: synthesis and structure activity relationship of 3-substituted derivatives of 2-hydroxypropioanilides. J Med Chem 31:954–959

    Google Scholar 

  • Zhao T, He G (1988) A phase II clinical trial of flutamide in the treatment of advanced breast cancer. Tumori 74:53–56

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Dipartimento di Fisiopatologia Clinica, Università di Torino, Via Genova, 3, I-10126, Torino, Italy

    Giuseppe Boccuzzi, Enrico Brignardello & Marco Di Monaco

  2. Department of Experimental Medicine and Oncology, General Pathology, University of Turin, Corso Rafaello 30, I-10125, Torino, Italy

    Elena Tamagno & Manuela Aragno

  3. Institute of General Pathology, University of Sassari, Via Padre Manzella 4, I-07100, Sassari, Italy

    Oliviero Danni

Authors
  1. Giuseppe Boccuzzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Elena Tamagno
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Enrico Brignardello
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Marco Di Monaco
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Manuela Aragno
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Oliviero Danni
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Boccuzzi, G., Tamagno, E., Brignardello, E. et al. Growth inhibition of DMBA-induced rat mammary carcinomas by the antiandrogen flutamide. J Cancer Res Clin Oncol 121, 150–154 (1995). https://doi.org/10.1007/BF01198096

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01198096

Key words

Search

Navigation